Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Steinberg

Showing results (311-320 of 481) with videos related to

Pageof 49
Sort By:
Plos One|May 26, 2010
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancerJin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, et al.
The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Pediatric Blood & Cancer|April 28, 2006
Treatment late effects in long-term survivors of pediatric sarcomaPatrick Mansky, Andrew Arai, Pamela Stratton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerJames L Gulley, Philip M Arlen, Anne Bastian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2011
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumorsShivaani Kummar, Mark Raffeld, Lamin Juwara, et al.
Transplantation and Cellular Therapy|August 11, 2021
Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host DiseaseDana A Schaar, Filip Pirsl, Noa Holtzman, et al.
The Oncologist|February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable ChordomaPeter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
JAMA Dermatology|February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical TrialAndrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Pageof 49

Showing results (311-320 of 481) with videos related to

Sort By:
Pageof 49
Plos One|May 26, 2010
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancerJin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, et al.
The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Pediatric Blood & Cancer|April 28, 2006
Treatment late effects in long-term survivors of pediatric sarcomaPatrick Mansky, Andrew Arai, Pamela Stratton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerJames L Gulley, Philip M Arlen, Anne Bastian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2011
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumorsShivaani Kummar, Mark Raffeld, Lamin Juwara, et al.
Transplantation and Cellular Therapy|August 11, 2021
Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host DiseaseDana A Schaar, Filip Pirsl, Noa Holtzman, et al.
The Oncologist|February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable ChordomaPeter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
JAMA Dermatology|February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical TrialAndrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Pageof 49